Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Anlotinib in ESCC after PD-1 failure
NCT05990231Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
cadonilimabanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05990231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990231.